# Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

> **NCT01276327** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Linagliptin + Pioglitazone
- **DRUG:** Linagliptin + Pioglitazone
- **DRUG:** Linagliptin/Pioglitazone
- **DRUG:** Linagliptin/Pioglitazone

## Key facts

- **NCT ID:** NCT01276327
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276327, "Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01276327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*